Next Article in Journal
A Retrospective Cohort Study of Safety Outcomes in New Zealand Infants Exposed to Tdap Vaccine in Utero
Previous Article in Journal
Dose Effects of Recombinant Adenovirus Immunization in Rodents
 
 
Search for Articles:
Title / Keyword
Author / Affiliation
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Vaccines
Volume 7
Issue 4
10.3390/vaccines7040146
vaccines-logo
Submit to this Journal Review for this Journal Edit a Special Issue
► Article Menu

Article Menu

share announcement question_answer thumb_up
...
textsms
...
Article

Evaluation of Pneumococcal Surface Protein A as a Vaccine Antigen against Secondary Streptococcus pneumoniae Challenge during Influenza A Infection

by
Sean Roberts
,
Clare M. Williams
,
Sharon L. Salmon
,
Jesse L. Bonin
,
Dennis W. Metzger
and
Yoichi Furuya
*
Department of Immunology and Microbial Disease, Albany Medical College, Albany, NY 12208, USA
*
Author to whom correspondence should be addressed.
Vaccines 2019, 7(4), 146; https://doi.org/10.3390/vaccines7040146
Received: 22 July 2019 / Revised: 27 September 2019 / Accepted: 2 October 2019 / Published: 11 October 2019
(This article belongs to the Section Vaccines against Infectious Diseases)
View Full-Text Download PDF
Browse Figures

Abstract

Secondary bacterial pneumonia is responsible for significant morbidity and mortality during seasonal and pandemic influenza. Due to the unpredictability of influenza A virus evolution and the time-consuming process of manufacturing strain-specific influenza vaccines, recent efforts have been focused on developing anti-Streptococcus pneumoniae immunity to prevent influenza-related illness and death. Bacterial vaccination to prevent viral-bacterial synergistic interaction during co-infection is a promising concept that needs further investigation. Here, we show that immunization with pneumococcal surface protein A (PspA) fully protects mice against low-dose, but not high-dose, secondary bacterial challenge using a murine model of influenza A virus-S. pneumoniae co-infection. We further show that immunization with PspA is more broadly protective than the pneumococcal conjugate vaccine (Prevnar). These results demonstrate that PspA is a promising vaccine target that can provide protection against a physiologically relevant dose of S. pneumoniae following influenza infection. View Full-Text
Keywords: influenza-pneumococcal co-infection; pneumococcal vaccination; pneumococcal surface protein A; Streptococcus pneumoniae; Prevnar influenza-pneumococcal co-infection; pneumococcal vaccination; pneumococcal surface protein A; Streptococcus pneumoniae; Prevnar
►▼ Show Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Supplementary Material

SciFeed

Share and Cite

MDPI and ACS Style

Roberts, S.; Williams, C.M.; Salmon, S.L.; Bonin, J.L.; Metzger, D.W.; Furuya, Y. Evaluation of Pneumococcal Surface Protein A as a Vaccine Antigen against Secondary Streptococcus pneumoniae Challenge during Influenza A Infection. Vaccines 2019, 7, 146. https://doi.org/10.3390/vaccines7040146

AMA Style

Roberts S, Williams CM, Salmon SL, Bonin JL, Metzger DW, Furuya Y. Evaluation of Pneumococcal Surface Protein A as a Vaccine Antigen against Secondary Streptococcus pneumoniae Challenge during Influenza A Infection. Vaccines. 2019; 7(4):146. https://doi.org/10.3390/vaccines7040146

Chicago/Turabian Style

Roberts, Sean, Clare M. Williams, Sharon L. Salmon, Jesse L. Bonin, Dennis W. Metzger, and Yoichi Furuya. 2019. "Evaluation of Pneumococcal Surface Protein A as a Vaccine Antigen against Secondary Streptococcus pneumoniae Challenge during Influenza A Infection" Vaccines 7, no. 4: 146. https://doi.org/10.3390/vaccines7040146

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Article Access Map by Country/Region

1
Back to TopTop